Background/Aims: Stem cells or progenitor cells have been demonstrated as a novel alternative for cell therapy; however, their sustained efficacy is still debated. This study aimed to evaluate whether interleukin 10 (IL-10) gene-edited amniotic mesenchymal stem cells (AMM/I) contribute to left ventricular (LV) function and remodeling after acute myocardial infarction (AMI). Methods: The IL-10 gene was integrated into the genomic locus of AMM via transcription activator-like effector nucleases (TALEN) and AMM/I were intramyocardially transplanted into AMI mice models. Cardiac function, quantitative polymerase chain reaction, histology, capillary density, and apoptosis assays were performed. Results: AMM/I transplantation significantly suppressed infiltrated CD68 positive or F4/80 positive inflammatory cells and reduced the expression of pro-inflammatory factors in the infarcted myocardium. In addition, significantly improved LV function and reduced infarct size was noted in mice model with AMM/I transplantation than in those given AMM. Moreover, AMM/I highly inhibited cell apoptosis and increased capillary density in the infarcted myocardium. Conclusion: Our study demonstrated that AMM/I recruitment played favorable roles in the early restoration of LV function and remodeling by suppressing inflammation and enhancing cardiac protection and capillary density.
Interleukin 10-Secreting MSCs via TALENMediated Gene Editing Attenuates Left Ventricular Remodeling after Myocardial Infarction
Die
Introduction
In Western societies, myocardial infarction (MI) is a major cause of death owing to the development of heart failure. One of the major pathologic determinants of cardiac diseases has been noted to be left ventricular (LV) remodeling due to fibrosis and dilation, leading to cardiac dysfunction and heart failure. This cardiac dysfunction has a strong association with inflammation in the heart [1, 2] . Pro-inflammatory cytokines and anti-inflammatory cytokines mediate homeostasis in damaged heart; however, sustained exposure to proinflammatory response could lead to heart failure owing to its association with increased matrix metalloproteinase production and extracellular matrix degradation [3, 4] . Thus, therapeutic strategies targeting inflammatory activity in heart disease have been applied to reduce cardiac remodeling [5] .
According to recent reports, stem cells contribute to tissue regeneration by paracrine effects or transdifferentiation [6, 7] . In addition, several studies have demonstrated that mesenchymal stem cells (MSCs) have anti-inflammatory properties via interleukin (IL) 10 and IL-1 receptor antagonist (IL-1Ra) secretion [8, 9] . IL-10 is one of the potent antiinflammatory factors that controls neutrophilic infiltration and deactivates various proinflammatory mediators [10] . In fact, paracrine factors secreted from MSCs facilitate favorable therapeutic outcomes [8, 9] . However, the low level of paracrine factors appears to be inadequate for efficient therapeutic efficacy due to the short half-life of paracrine proteins, which poses a big challenge for stem cell research and regenerative medicine.
Transfection and selection
Human AMMs were maintained in DMEM supplemented with 10% FBS. For electroporation, human AMMs were harvested and counted; 1 × 10 5 cells were resuspended with 0.6 μg of AAVS1 left TALENuclease vector (System Biosciences), AAVS1 right TALE-Nuclease vector (System Biosciences) and AAVS1 HR Donor (System Biosciences) in 10 μL electroporation buffer, and the cells were electroporated using a Neon Transfection System (Thermo Fisher Scientific). After 4 days of transfection, IL-10 knock-in cells were selected by incubating them in 5 μg/mL puromycin for 7 days.
Fluorescence-activated cell sorting
After puromycin selection, the cells were harvested on day 50. Cells were washed once with phosphatebuffered saline (PBS) following the 0.05% trypsin/EDTA treatment for cell detachment. The cells were resuspended in PBS for sorting. The cells were sorted on an S3e Cell Sorter (Bio-Rad, Hercules, CA, USA).
Genomic DNA extraction and junction polymerase chain reaction Genomic DNA from cultured cells was extracted using a G-spin™ Total DNA Extraction Mini Kit (Intron Biotechnology) according to the manufacturer's instructions. Next, 120 ng of genomic DNA was amplified by touch-down polymerase chain reaction (PCR) (36 cycles). The touch-down PCR conditions were as follows: 1 cycle at 98 °C for 30 s, followed by 22 cycles of 98 °C for 30 s, 72-60 °C for 30 s (a decrease of 1 °C every two cycles) and 72 °C for 1 min, followed by 14 additional cycles at 98 °C for 30 s, 60 °C for 30 s, and 72 °C for 1 min, and the final extension step at 72 °C for 10 min. For the second PCR, 0.5 μL of the touch-down PCR product was used. The second PCR conditions were as follows: 1 cycle at 98 °C for 30 s, followed by 35 cycles at 98 °C for 30 s, 65 °C for 30 s, and 72 °C for 1 min, with a final extension step at 72 °C for 10 min. PCR primer were used as following; Forward (J212) : aactctgccctctaacgctg, (J195) : cgaggccagaggccacttgtgta.
Quantitative reverse transcriptase-PCR (qRT-PCR) and reverse transcriptase-PCR (RT-PCR) analyses
qRT-PCR or RT-PCR analysis was conducted as described in a previous study [13] [14] [15] . Briefly, the total RNA was isolated from the cells using RNA-stat (Iso-Tex Diagnostics, Friendswood, TX, USA). The extracted RNA was reverse-transcribed using Taqman Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. The synthesized cDNA was subjected to qRT-PCR or RT-PCR using human-specific primers and probes. RNA levels were quantitatively assessed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). The relative mRNA expression normalized to GAPDH expression was calculated as described previously [16] .
qPCR and RT-PCR primer
The primers used in qRT-PCR were for human IL-10 (Hs00237017_m1) and GAPDH (Hs99999905_ m1) and for mouse IL-1β (Mm00434228_m1, IL-6 (Mm00446190_m1), tumor necrosis factor α (TNF-α) (Mm00443259_g1), monocyte chemoattractant protein 1 (MCP-1) (Mm00441242_m1), fibroblast growth factor-2 (FGF-2) (Mm01285715_m1), insulin growth factor-1 (IGF-1) (Mm00439561_m1), stromal cell-derived factor 1α (SDF-1α) (Mm00445552_m1), vascular endothelial growth factor A (VEGF-A) (Mm01281448_g1), and GAPDH (Mm99999915_g1). The following paired RT-PCR primers were used: GAPDH (Hs00761525_CE, 268 bp), IL-10 (Hs00564257_CE, 274bp). All of the primer/probe sets were purchased from Applied Biosystems.
Microarray analysis
Microarray analysis was performed using the Clariom S Human Array (Affymetrix, Santa Clara, CA, USA). The data were summarized and normalized with the robust multiaverage (RMA) method implemented in Affymetrix® Power Tools. We exported the results of the gene level RMA analysis and performed differentially expressed gene analysis. The statistical significance of the expression data was determined through fold change. Hierarchical cluster analysis was performed using complete linkage and Euclidean distance as a measure of similarity. 6 cells each) were seeded into T-75 cell culture flasks and grown in normal medium or low-glucose DMEM (Gibco) containing 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco) for 48 h until the cells reached approximately 80% confluence. Culture media (CM) from each sample was then centrifuged at 1, 000xg for 5 min and the supernatants were collected and used as CM. In vitro IL-10 secretion levels of AMM and AMM/I CM were assessed by using IL-10 ELISA kit (Abcam, Cambridge, MA, USA).
Cell transplantation in MI models
All experimental protocols were approved by the Dong-A University Institutional Animal Care and Use Committee and all procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The AMI model was induced as described in previous literature [17] . Male athymic nude mice (Joongang Laboratory Animal Inc., Seoul, South Korea), aged between 7 to 10 weeks and weighing between 19 to 23 g were used. To induce AMI, the mice were anesthetized (75 mg/kg ketamine, 1 mg/kg medetomidine, and 600 mg/kg atropine) and were administered buprenorphine (0.05 mg/kg); the depth of anesthesia was monitored by the respiratory rate and lack of withdrawal reflex upon toe pinching. The mice were intubated with a 22-gauge intravenous catheter and artificially ventilated with a mechanical ventilator under anesthesia using isoflurane. After opening the chest, the left anterior descending artery was ligated using 8.0 polypropylene sutures. The apex of the LV was observed for evidence of akinesia and myocardial blanching, indicating interruption of coronary flow. After induction of MI, 1 × 10 6 AMM, AMM/I in PBS (50 µL), or the same volume of PBS alone, were directly injected into the peri-infarct areas (three sites). Cardiac function was examined using VisualSonics Vevo 2100 with a 40-MHz transducer (Visualsonics, Toronto, Ontario, Canada), and left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) were calculated as described previously [18] . Euthanasia was performed by intravenous injection of thiopental-sodium (40 mg/kg).
Histological analysis
Mice hearts were harvested and fixed for 4 h in 4% paraformaldehyde and incubated overnight in 15% sucrose solution. The tissues were embedded in OCT compound (Sakura Finetek, Torrance, CA, USA), snapfrozen in liquid nitrogen, and sectioned (thickness, 10-20 µm) [19] . Tissue sections were permeabilized and stained with anti-CD68 (1:200; Serotec, Raleigh, NC, USA) and followed by secondary antibody. CD68-positive cells, as number per high-power visual field, were assessed at randomly selected parts of the border zone of infarcted hearts. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (1:5000; Sigma Aldrich, St. Louis, MO, USA). For capillary density measurement, five frozen sections of tissue from each group were stained with primary biotinylated ILB4 (1:250; Vector Laboratory Inc., Burlingame, CA, USA) and secondary strepta-avidin Alexafluor 488 (1:400; Invitrogen). Five fields from four tissue sections were randomly selected, and the number of capillaries was counted in each field. Photographs were taken using fluorescent inverted microscopy or confocal microscopy. To examine apoptosis, TdT-mediated dUTP nick-end labeling (TUNEL) reaction was conducted using fluorescein in situ cell death detection kit (RocheMolecular, Indianapolis, IN, USA) [20] . The fibrosis area and infarction area were examined by the computer software Image-Pro Plus after Masson's trichrome staining as previously described [21, 22] .
Statistical analysis
All data were presented as mean ± standard deviation. Statistical analyses were performed with Student's t test for comparisons between two groups, and analysis of variance followed by Bonferroni's correction was performed for more than two groups using SPSS version 11.0 (IBM Corp., Armonk, NY, USA) [14, 15] . A p value <0.05 was considered statistically significant. Graphs were drawn using MedCalc software® (Mariakerke, Belgium).
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Results
Targeted knock-in of IL-10 into the AAVS1 safe harbor locus
To establish a stable stem cell line expressing the anti-inflammatory gene IL-10 using the TALEN-mediated integration method, we chose AAVS1, known as a safe locus for stable transgene expression, on chromosome 19 as the target integration site. The targeting donor plasmid DNA was designed to carry PGK promoter-driven IL-10 and EF1α promoter-driven GFP-T2A-puromycin (Fig. 1A) . The donor plasmid was transfected into human AMMs with a pair of TALENs, leading to cleavage of the AAVS1 locus. Although less than 6% of cells were GFP-positive cells after transfection, we increased the ratio of IL-10 knock-in GFP-positive cell to 99.6% by fluorescence-activated cell sorting and puromycin drug selection (Fig.  1C) . To confirm the genomic integration of the donor plasmid into AAVS1, we performed genomic DNA PCR followed by touch-down PCR. The correct insertion of the donor plasmid was confirmed by 5′-junction fragment (960-bp) amplification (Fig. 1B) . Next, we confirmed the IL-10 expression in transfected AMMs by qRT-PCR, which was significantly higher than that of AMM-untreated control cells, indicating the successful generation of AMM/I (Fig. 1D) . 
Global gene expression profile of AMM/Is
To investigate the genetic characteristics of AMM/I in detail, we conducted microarray analysis compared with untreated AMMs (Fig. 2A) . The global gene expression analysis revealed that IL-10 (94.5-fold) was the most highly expressed gene, suggesting successful integration of the IL-10 gene in the AAVS1 locus (Table 1) . However, we detected relatively low levels of other genes (less than 6-fold) such as NPNT, KDM4C, PCDH7, and CRABP1. These data indicate that TALEN-mediated gene integration does not allow severe off-target mutagenesis in target cells.
Next, to evaluate the quantity of IL-10 secreted by AMM/I, we conducted ELISA. ELISA detected significantly higher levels of IL-10 in AMM/I CM than in AMM CM (Fig. 2B) .
AMM/I suppress inflammation in the ischemic myocardium
To examine the anti-inflammatory effects of AMM/I in cardiac tissue, we induced mice MI models and performed immunohistochemical staining using CD68 antibody 3 days after cell injection. Lower numbers of infiltrated CD68-positive cells (Fig. 3A and 3B ) and F4/80-positive cells (Fig. 3C and 3D) were detected in the AMM/I-injected mice than in the AMMand PBS-injected mice in the border zone of the infarcted LV heart tissues. In addition, higher levels of IL-10 protein and mRNA were detected in AMM/I injected LV heart tissues than in AMM injected LV heart tissues ( Fig. 3E and 3F) .
Next, we also measured the mRNA expression levels of pro-inflammatory factors in the infarcted heart tissues 3 days after cell injection. The AMM/I-injected mice showed significantly lower IL-1β, IL-6, and TNF-α mRNA expressions than did the AMM-and PBSinjected mice in infarcted heart tissues (Fig. 3G) . 
AMM/I exert favorable therapeutic effects in MI model
To examine the therapeutic effects of AMM/I in MI, the LV function was examined by echocardiography at 2 and 4 weeks. AMM-and PBS-injected mice were used as control groups. We could not find any significant differences in LV function at 2 weeks. However, echocardiography data at 4 weeks showed that the EF and FS were significantly greater in the AMM/I-injected mice compared with that of the AMM-or PBS-injected mice (Fig. 4A and  4B) . Next, the infarct size in the heart tissue was also measured after cell injection at 4 weeks post-MI using Mason's trichrome (MT) staining. MT staining results revealed that the significantly lower circumferential fibrosis area and infarction area were detected in AMM/Iinjected mice compared with that of the AMM-and PBS-injected mice (Fig. 5A , 5B and 5C).
AMM/I injection decreases apoptotic cells and increases vascular density in ischemic heart
Because decreased infarct areas in heart tissue are associated with cell apoptosis, TUNEL assay was conducted using tissue sections harvested at 4 weeks. The apoptotic cells at the peri-infract area were significantly lower in the AMM/I-injected mice group than in 
the AMM-and PBS-injected groups ( Fig. 6A and 6B ). Capillary density was also observed post-AMM transplantation in ischemic heart tissues. Interestingly, vascular density in the border zone of the ischemic heart area was significantly higher in the AMM/I-injected mice than that of the AMM-and PBS-treated mice ( Fig. 6C and 6D ).
To determine the angiogenic humoral effects after AMM/I injection on MI mice, ischemic cardiac tissues were prepared at 4 weeks after cell injection. Interestingly, the mRNA expression levels of FGF-2, IGF-1, SDF-1α and VEGF-A were significantly upregulated in the AMM/I-injected ischemic cardiac tissues compared with the AMM-or PBS-injected cardiac tissues (Fig. 7) . These data suggest that direct cardiac injection of AMM/I also influences the enhanced multiple pro-angiogenic factors.
Discussion
In the present study, we first demonstrated that IL-10-edited AMMs exhibited robust anti-inflammatory activity, suggesting that this could be one of the promising therapeutic options in the treatment of ischemic heart disease. The major results of this study are as follows: (1) We successfully generated sustainable IL-10-expressing AMM cell line via genome editing. (2) AMM/I showed anti-inflammatory properties in AMI mice models. (3) AMM/I transplantation into the AMI mice model resulted in enhanced recovery of heart function and attenuated LV remodeling. (4) The transplanted AMM/I lessened the inflammatory response and provided a favorable environment for neovascularization.
One challenging issue in stem cell therapy is its marginal influence in treating various ischemic or chronic diseases. To overcome this limitation, genetic modification has been regarded as an attractive tool as it can provide protein replacement as a cellular vehicle. However, genetic modification also has been limited by random insertional mutagenesis. Until recently, to remove the risk of genomic mutagenesis in genetic modification, the technology of targeted gene insertion at safe-harbor genomic sites, namely, gene editing, has generated great interest. For gene insertion, only few genomic sites are safe and in an open chromosomal status to achieve high gene expression. In fact, erythropoietin gene-edited MSCs, hepatocyte growth factor gene-edited MSCs, and chemokine gene-edited AMM cell lines were recently generated for therapeutic proteins by zinc finger nuclease or TALEN mediators [11, 23] . In agreement with these studies, we were also able to successfully generate (TALEN-mediated) IL-10-integrated AMM lines without high-level genetic mutagenesis in the genome, as confirmed by the global gene expression profile derived from the microarray data. However, AMM/I expressed several genes less than 6-folds when compared to untreated AMMs, indicating a relatively low level of off-target mutagenesis or innate cellular autocrine influence of IL-10 in AMMs. These results are in agreement with a previous report that the incidence of off-target mutation is sufficiently low for the TALEN- [12] . According to recent reports, LV remodeling such as cardiomyocyte hypertrophy is strongly associated with inflammatory response that alters gene expression and induces contractile abnormalities and ventricular dysfunction [24, 25] . Inflammatory cell infiltration was also strongly associated with increase in stress-activated cytokines, such as IL-1β, IL-6, TNF-α, and MCP-1, produced by cardiomyocytes and inflammatory cells [26] . In fact, T-lymphocytes derived from post-MI resulted in cytotoxicity of the cardiac myocytes [27] . To reduce the inflammatory reaction in the injury site, IL-10 was used. IL-10 administration attenuated the infiltration of inflammatory cells in the vascular injury model [28] . In line with this study, AMM/I injection inhibited the infiltration of CD68-positive monocyte/ macrophages and the expression of pro-inflammatory cytokines in the border zone of the ischemic myocardium.
Cytokines contribute to adverse LV remodeling and contractile performance through its effects on calcium-mediated cardiac contractility [29, 30] . IL-10 administration attenuated left ventricular remodeling after MI [26] , and injection of IL-10-secreting bone marrow mononuclear cells improved cardiac function in infarcted mouse hearts, which led to a significant improvement in cardiac function [31] . In the present study, AMM/I transplantation also attenuated the decrease of FS and EF after MI. These findings strongly support the evidence of the cardioprotective effects of IL-10 on infarcted heart tissue. However, more studies on IL-10 and a more detailed study of the therapeutic mechanisms such as calciummediated cardiac contractility might be required.
Neovascularization is an essential part for the healing process of an ischemic heart, and IL-10 treatment increased CD31-positive capillaries at 4 weeks post-MI [26] . Other studies also reported the involvement of inflammatory mediators in myocyte apoptosis or necrosis in the progression of adverse LV remodeling [32] and that IL-10 treatment decreased the apoptotic cells in the MI mice model [26] . Recently, the robust angiovasculogenic and chemotactic properties of AMMs themselves have been reported [33, 34] . In line with these previous reports, in the present study, increased capillary density, pro-angiogenic factors, and lower apoptotic cells in ischemic cardiac tissues were observed in the AMM/I-treated MI group than in AMM-treated MI group. These results suggest that an anti-inflammatory environment could lead to synergistic effects for optimal neovascularization in MI.
These results are similar to previously reported data that human cultured BM-derived CD31 + cells, which possess both angiogenic and anti-inflammatory properties, are effective for cardiac and vascular repair [21] . Thus, AMM/I have the potential of robust cardiac protection by secreting the angiogenic [33, 34] and anti-inflammatory factor IL-10. The immune-regulatory mechanism regarding IL10 and infiltrating inflammatory cells in heart tissues has been elucidated by emerging research. IL-10 modulates the secretion of Th1 and Th2 cell cytokines and activation/proliferation of T lymphocytes [35] . Previous studies have demonstrated that IL-10 null mice showed 75% mortality due to the larger infarct size and increased plasma levels of TNF-α, indicating enhanced inflammation [36] . Our data also demonstrated that IL-10 derived from AMM/I acted via modulation of infiltrating inflammatory cells such as CD68
+ or F4/80 + macrophages and contributed to cardiac protection and paracrine activities of infused cells after MI.
Conclusion
Taken together, the present study suggests that AMM/I produced by gene editing contributes to the prevention of LV remodeling and to cardiac protection by the attenuation of severe pro-inflammatory responses with effects on angiogenesis after MI. Accordingly, AMM/I generated by TALEN gene editing might be a highly promising and therapeutic option to treat MI. Further studies might be required to determine whether AMM/I are safe and capable of treating ischemic cardiovascular disease in the clinical setting.
